[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611354":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":43,"collaborators":19,"id":46,"slug":19,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":19,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":19,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":69,"whyStopped":19,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Temporal interference stimulation","EXPERIMENTAL","Patients with hypertension\u002Fhypotension assigned to temporal interference stimulation for 20 min per session.",[13],"Other: Temporal Interference",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Temporal Interference","The intervention will consist of 5 days of 20-min temporal interference stimulation.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Liankun Ren, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","+86 13681576621","renlk2022@outlook.com",[30],{"facility":31,"status":19,"city":32,"state":19,"zip":19,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Xuanwu Hospital,Capital Medical University, Beijing, Beijing 100053","Beijing","China",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41,42],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":23,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Liankun_Ren","Professor","100611354",false,"NCT07239492","Efficacy and Safety Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Regulation","Efficacy and Safety Evaluation of Transcranial Non-invasive Temporal Interference Stimulation for Blood Pressure Regulation: A Pilot, Prospective Study","Inclusion Criteria:\n\n1. Age: 18-65 years old, male or female;\n2. Three groups of patients will be enrolled in the study:\n\n   1. Essential Hypertension Grade 1 (Low Risk) - Antihypertensive Medication-Naive Group: No other cardiovascular risk factors or disease history, with systolic blood pressure (SBP) ≥140 mmHg and \\\u003C160 mmHg and\u002For diastolic blood pressure (DBP) ≥90 mmHg and \\\u003C100 mmHg;\n   2. Essential Hypertension - Refractory Hypertension Group: Meeting one of the following conditions after intensive lifestyle intervention plus taking 3 different types of antihypertensive drugs (including thiazide diuretics) for ≥4 weeks, with each drug at the maximum dose or maximum tolerated dose: Clinic blood pressure ≥140\u002F90 mmHg and 24-hour average ambulatory blood pressure ≥130\u002F80 mmHg, or average home blood pressure ≥135\u002F85 mmHg; or blood pressure can only be controlled below 140\u002F90 mmHg with ≥4 types of antihypertensive drugs;\n   3. Neurogenic Orthostatic Hypotension (nOH) Group: A decrease in SBP ≥20 mmHg and\u002For DBP ≥10 mmHg within 3 minutes of the head-up tilt test (HUTT) and\u002For standing activity;\n3. BMI: 18-30;\n4. After being informed of the potential risks, the patient agrees to participate in this study and signs the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Patients with secondary hypertension;\n2. Patients with intracranial structural lesions (e.g., infarcts, vascular malformations, space-occupying lesions, etc.);\n3. Pregnant women;\n4. Individuals unable to cooperate due to mental illness or other reasons;\n5. Those who have participated in other clinical studies within the past 3 months;\n6. Patients who apply to withdraw from this clinical study for any reason;\n7. Patients with cardiac insufficiency;\n8. Patients excluding those with white coat effect;\n9. Individuals with a high risk of cerebrovascular disease confirmed by transcranial magnetic resonance imaging (MRI).","ALL","18 Years","65 Years",{"count":56,"type":57},25,"ESTIMATED","INTERVENTIONAL",[60],"NA","The primary objective of this research is to study the efficacy and safety of temporal interference stimulation for regulating the blood pressure.",[63,64],"Hypertension","Hypotension",[66,67,68],"hypertension","temporal in terference","hypotension","NOT_YET_RECRUITING","2025-11-15",{"date":72,"type":73},"2025-11-20","ACTUAL",{"date":75,"type":57},"2025-12-01",{"date":77,"type":57},"2027-01-01",{"name":5,"class":6},1]